{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-26-000013","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.809908+00:00","generated_at":"2026-05-15T19:24:47.423770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026","bullets":["Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.","FY2025 net loss $88.1M ($1.00/share); Q4 net loss $27.4M ($0.27/share).","Pemvidutide granted FDA Breakthrough Therapy Designation for MASH; Phase 3 trial planned in 2026.","Topline data from RECLAIM Phase 2 trial in alcohol use disorder expected Q3 2026.","Jerry Durso appointed CEO; previously CEO of Intercept Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-26-000013","json":"https://secwatch.observer/filing/0001326190-26-000013.json","markdown":"https://secwatch.observer/filing/0001326190-26-000013.md","text":"https://secwatch.observer/filing/0001326190-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/0001326190-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/alt-20260305x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:24:47.423770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"420f57f224c6b6767c8e806496a3d8f15c3b10bd","claim":"Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/0001326190-26-000013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}